"On Tuesday, pharmaceutical outlet Endpoints News reported that Tidmarsh had said, "I'm going to fight it. It's my name and credibility," and told senior FDA staffers, via an intermediary, that he's not resigning. It's not clear how he plans to fight the lawsuit going forward: Tidmarsh did resign on Sunday, he told Endpoints, and Hilliard told SFGATE the move was "effective immediately.""
"Whatever's next, he'll do it with a cloud of allegations hanging over his head. The lawsuit filed on Sunday by Aurinia Pharmaceuticals didn't pull any punches. It accused Tidmarsh of defaming Aurinia while at his FDA post and sinking the company's market cap by over $350 million, all because of a "longstanding personal vendetta" against biotech mogul and Aurinia board chair Kevin Tang."
George Tidmarsh moved from academia and biotech into the FDA's top drug-center role in July after a career at Stanford and in California biotech companies. HHS placed him on leave as officials reviewed "serious concerns about his personal conduct," and Aurinia Pharmaceuticals filed a lawsuit accusing him of defaming the company and causing a more than $350 million decline in market capitalization tied to an alleged vendetta against board chair Kevin Tang. Tidmarsh initially indicated he would fight the claims and told staff he was not resigning, but he resigned effective immediately and remains under scrutiny.
Read at SFGATE
Unable to calculate read time
Collection
[
|
...
]